Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of sublingual immunotherapy with Pru p 3 in nsLTP allergy
2017-005038-53Phase 3Active
- Sponsor
- Fundación IMABIS
- Start
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lipid transfer protein allergy, food allergy, Artemisia pollinosis and 1 more comparing SLIT Pru p 3 with Placebo (2 arms). Primary endpoint: Evaluation of the in vivo response. Started Nov 2018; status: active.
02
Drugs
Pru p 3
03
Conditions
lipid transfer protein allergyfood allergyArtemisia pollinosispollinosis
Beyond the preview
Go deeper on 2017-005038-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005038-53.